MPH MD - FibroGen Ex Officer
| FGEN Stock | USD 0.39 0.01 2.50% |
Insider
MPH MD is Ex Officer of FibroGen
| Age | 58 |
| Address | 409 Illinois Street, San Francisco, CA, United States, 94158 |
| Phone | 415 978 1200 |
| Web | https://www.fibrogen.com |
FibroGen Management Efficiency
The company has return on total asset (ROA) of (0.2655) % which means that it has lost $0.2655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.3. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.Similar Executives
| Showing other executives | INSIDER Age | ||
| Hennie Hoogenboom | Merus BV | N/A | |
| Brian MBA | Agios Pharm | 55 | |
| Richard Goold | Lyell Immunopharma | 64 | |
| Robert Blanks | Ardelyx | 64 | |
| Cecilia Geuijen | Merus BV | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Jenna Cohen | Blueprint Medicines Corp | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Sean Flynn | Verastem | 50 | |
| Jack Anders | Revolution Medicines | 47 | |
| Prof MD | Lyell Immunopharma | N/A | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| Anjali Ganguli | Syndax Pharmaceuticals | 47 | |
| Keith CPA | Syndax Pharmaceuticals | 53 | |
| MBA MBA | Biomarin Pharmaceutical | 71 | |
| Philip Scalzo | Biomarin Pharmaceutical | N/A | |
| Ashish MBA | Vaxcyte | 52 | |
| Margaret JD | Revolution Medicines | 61 | |
| Crystal MD | Lyell Immunopharma | 63 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
Management Performance
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.27 |
FibroGen Leadership Team
Elected by the shareholders, the FibroGen's board of directors comprises two types of representatives: FibroGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroGen. The board's role is to monitor FibroGen's management team and ensure that shareholders' interests are well served. FibroGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kirk MBA, Chief Officer | ||
| Rahul Kaushik, Technical Development | ||
| Mr JD, Chief Officer | ||
| Enrique Conterno, CEO Director | ||
| Barry Berkowitz, Founder | ||
| Christine Chung, Senior Operations | ||
| David DeLucia, Vice Relations | ||
| Thane Wettig, CEO Director | ||
| Elizabeth PharmD, Biometrics, Regulatory | ||
| Elias Kouchakji, Drug Devel | ||
| Juan Graham, Chief Officer | ||
| Julian Stern, Secretary | ||
| Karen Bergman, Vice President Investor Relations and Corporate Communications | ||
| Deyaa MD, Senior Officer | ||
| Tricia Stewart, Chief Officer | ||
| MPH MD, Ex Officer | ||
| John Hunter, Chief Officer |
FibroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.16 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.97) % | ||||
| Operating Margin | (0.22) % | ||||
| Current Valuation | (12.37 M) | ||||
| Shares Outstanding | 100.77 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 55.00 % | ||||
| Number Of Shares Shorted | 4.32 M | ||||
| Price To Earning | 97.67 X |
Pair Trading with FibroGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will appreciate offsetting losses from the drop in the long position's value.Moving against FibroGen Stock
The ability to find closely correlated positions to FibroGen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroGen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroGen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroGen to buy it.
The correlation of FibroGen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroGen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroGen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroGen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (1.23) | Revenue Per Share 1.758 | Quarterly Revenue Growth 0.143 | Return On Assets (0.27) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.